# KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

> **NCT00085943** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 866 (—)

## Conditions studied

- HIV Infection
- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** LEXIVA (GW433908)
- **DRUG:** Ritonavir
- **DRUG:** KALETRA
- **DRUG:** EPIVIR
- **DRUG:** Ziagen
- **DRUG:** Abacavir/Lamivudine
- **DRUG:** Fosamprenavir

## Key facts

- **NCT ID:** NCT00085943
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 866 (—)
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085943, "KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00085943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*